Filtered By:
Condition: Atrial Fibrillation
Procedure: Heart Transplant
This page shows you your search results in order of date. This is page number 4.
Order by Relevance | Date
Total 240 results found since Jan 2013.
Social bias in artificial intelligence algorithms designed to improve cardiovascular risk assessment relative to the Framingham Risk Score: a protocol for a systematic review
This study will employ an equity-lens to identify sources of bias (ie, race/ethnicity, gender and social stratum) in ML algorithms designed to improve CVD risk assessment relative to the FRS. A comprehensive literature search will be completed using MEDLINE, Embase and IEEE to answer the research question: do AI algorithms that are designed for the estimation of CVD risk and that compare performance with the FRS address the sources of bias inherent in the FRS? No study date filters will be imposed on the search, but English language filters will be applied. Studies describing a specific algorithm or ML approach that provid...
Source: BMJ Open - May 31, 2023 Category: General Medicine Authors: Garcha, I., Phillips, S. P. Tags: Open access, General practice / Family practice Source Type: research
Po-04-151 a new sequential artificial intelligence algorithm for predicting atrial fibrillation using serial 12-lead electrocardiograms
Because the early stage of atrial fibrillation (AF) is difficult to detect, a significant number of patients are exposed to the risk of stroke without forewarning. Artificial intelligence (AI) algorithms using 12-lead electrocardiograms (ECGs) are being developed to detect AF early.
Source: Heart Rhythm - May 1, 2023 Category: Cardiology Authors: Jihoon Choi, Kyoung-Min Park Source Type: research
Dh-452784-2 identifying atrial fibrillation with sinus rhythm electrocardiogram using artificial intelligence in embolic stroke with undetermined source
Previous studies have demonstrated acceptable ranges of accuracy of artificial intelligence (AI) algorithms for identifying patients with paroxysmal atrial fibrillation (AF) based on their sinus rhythm electrocardiograms (ECGs). However, none of them has been validated in patients with embolic stroke with undetermined source (ESUS) in which thorough AF screening is required.
Source: Heart Rhythm - May 1, 2023 Category: Cardiology Authors: Ji Hyun Lee, Youngjin Cho, Joonghee Kim Source Type: research
Artificial Intelligence for the Detection and Treatment of Atrial Fibrillation
AF, the most common clinically relevant cardiac arrhythmia, is expected to affect>5 million Americans by 2050.1 The diagnosis is frequently associated with other cardiovascular comorbidities, including hypertension, obesity and sleep apnoea, and AF is an important risk factor for stroke, heart failure and overall mortality.2 –4 Although treatment is available, many people remain untreated becau...
Source: Radcliffe Cardiology - April 19, 2023 Category: Cardiology Authors: c242508f1d9059bc0f2aa9bdd5421ba2 Source Type: research
New VOYAGER PAD Analysis Confirms Consistent Benefit of XARELTO ® (rivaroxaban) Plus Aspirin Following Lower Extremity Revascularization (LER)
TITUSVILLE, NJ, March 5, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from a new prespecified analysis from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefits of the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) over standard of care (aspirin alone), demonstrating consistent benefit at 30 days, 90 days and up to three years following LER in patients with PAD. Lower extremity revascularization, also called peripheral revascularization, is a procedure that restores blood flow in blocked arteries or veins. This analysis of ...
Source: Johnson and Johnson - March 5, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Real-World Study Confirms Benefit of XARELTO ® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
TITUSVILLE, NJ, December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO® (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a broad cohort of patients with various cancer types. Patients with CAT are at a higher risk of venous thromboembolism (VTE), which is the second-leading cause of death in people with cancer.1Data from the Observational Study in Cancer-A...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Diagnosis of Obstructive Sleep Apnea in Patients with Associated Comorbidity
Adv Exp Med Biol. 2022;1384:43-61. doi: 10.1007/978-3-031-06413-5_4.ABSTRACTObstructive sleep apnea (OSA) is a heterogeneous disease with many physiological implications. OSA is associated with a great diversity of diseases, with which it shares common and very often bidirectional pathophysiological mechanisms, leading to significantly negative implications on morbidity and mortality. In these patients, underdiagnosis of OSA is high. Concerning cardiorespiratory comorbidities, several studies have assessed the usefulness of simplified screening tests for OSA in patients with hypertension, COPD, heart failure, atrial fibril...
Source: Advances in Experimental Medicine and Biology - October 10, 2022 Category: Research Authors: F élix Del Campo C Ainhoa Arroyo Carlos Zamarr ón Daniel Álvarez Source Type: research
Protocol for Home-Based Solution for Remote Atrial Fibrillation Screening to Prevent Recurrence Stroke (HUA-TUO AF Trial): a randomised controlled trial
The objective of the study was to explore the use of long-term home-based ECG monitoring for AF detection and stroke prevention in patients with a history of stroke.
Methods and analysis
This prospective, randomised, open-label trial with blinded endpoint adjudication aimed to evaluate the efficacy of long-term home-based ECG monitoring for AF detection and stroke prevention in a 24-month period. Patients aged >18 years with a history of ischaemic stroke will be stratified according to the time from the index ischaemic stroke: <1, 1–3 and >3 years and then randomised in 1:1 to (1) home-based AF screening an...
Source: BMJ Open - July 15, 2022 Category: General Medicine Authors: Wong, C. K., Hai, J. J., Lau, Y.-M., Zhou, M., LUI, H.-W., Lau, K. K., Chan, K.-H., Mok, T. M., Liu, Y., Feng, Y., Tan, N., Tam, W.-C., Tam, K.-C., Feng, X., Zuo, M.-L., Yin, L.-X., Tan, J., Zhang, W.-J., Jiang, X., Huang, X., Ye, J., Liang, Y., Jiang, W. Tags: Open access, Cardiovascular medicine Source Type: research
New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news
Assessment of Hypertension, Guideline-Directed Counseling, and Outcomes in the ACHD Population
AbstractGuidelines for the diagnosis and treatment of hypertension were published by the American Heart Association (AHA) in 2017. The prevalence of hypertension in adults with congenital heart disease (ACHD) under these guidelines has yet to be characterized. We sought to assess the prevalence, impact, and provider response to hypertension under current guidelines. Data were obtained retrospectively from records of routine clinic visits over a 10 year period. Potential hypertension-related adverse outcomes including stroke, myocardial infarction, surgical intervention for aortic aneurysm, aortic dissection, atrial fibri...
Source: Mammalian Genome - April 5, 2022 Category: Genetics & Stem Cells Source Type: research
